June 9, 2021

BioLamina AB and partners granted € 6.1M in funding to develop organ-on-chip system for animal-free modelling of human diseases

BioLamina (Stockholm), together with six other esteemed European partners within industry and academia, will develop a user-friendly, next-generation gut-brain axis organ-on-chip (OoC) to study virus disease transmission and treatment.

The project, GUTVIBRATIONS, is funded by the European Commission through the Next Generation Organ-On-Chip Call (DT-NMBP-23) and combines expertise in the fields of OoC technology, 3D printing, bioengineering, organoids, virology, immunology, and cell culture to develop an animal-free, gut-brain axis OoC model that better mimics the human physiology.

Organ-on-chip technologies hold promise to accurately and better than animal models, mimic human organs and organ systems in vitro, and have great potential to be game-changing in life science research, drug discovery, and drug development. One of the major obstacles that face the broader implementation of OoCs is that most of these models are hard to use. “We are excited to be part of developing this next generation organ-on-chip technology, with user-friendliness in mind. The project will also include validation against existing clinical data. GUTVIBRATIONS has the potential to commercialize a very useful lab tool and fast-track drug development that ultimately will minimize costs, lower disease burden, and save lives,” says Dr. Therese Kallur, Director of Business Development at BioLamina.

For more information, please contact:

BIOLAMINA AB

Therese Kallur, Director of Business Development
Phone: +46 70 766 00 08
E-mail: communications@biolamina.com
Press images: www.biolamina.com/press-room-images

See also: https://gutvibrations.org